Digestive System Neoplasm

One patient participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G12D and was wild type for KRAS, PIK3CA, and… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

NRAS mutations have also been observed in melanoma and biliary tract, bladder, cervix, liver, lung, myeloid leukemia, ovarian, pancreatic, and thyroid cancer.

PMID 17384584 · Schubbert et al., 2007 · Open in CIViC

In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabiliza… (full text at CIViC)

PMID 22392911 · Migliardi et al., 2012 · Open in CIViC

NRAS mutations have also been observed in melanoma and biliary tract, bladder, cervix, liver, lung, myeloid leukemia, ovarian, pancreatic, and thyroid cancer.

PMID 17384584 · Schubbert et al., 2007 · Open in CIViC

NRAS mutations have also been observed in melanoma and biliary tract, bladder, cervix, liver, lung, myeloid leukemia, ovarian, pancreatic, and thyroid cancer.

PMID 17384584 · Schubbert et al., 2007 · Open in CIViC

In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabiliza… (full text at CIViC)

PMID 22392911 · Migliardi et al., 2012 · Open in CIViC

In an in vitro study, a DiFi colorectal cancer cell line stably expressing NRAS G12V mutation demonstrated resistance to cetuximab treatment compared to DiFi cells expressing wild-type NRAS. Resistanc… (full text at CIViC)

PMID 22797062 · Kasper et al., 2013 · Open in CIViC

NRAS mutations have also been observed in melanoma and biliary tract, bladder, cervix, liver, lung, myeloid leukemia, ovarian, pancreatic, and thyroid cancer.

PMID 17384584 · Schubbert et al., 2007 · Open in CIViC

In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabiliza… (full text at CIViC)

PMID 22392911 · Migliardi et al., 2012 · Open in CIViC

In an in vitro study, an OXCO-2 cell line expressing NRAS G13D mutation demonstrated acquired resistance after low level cetuximab exposure compared to OXCO-2 parental cells expressing NRAS wild-type.… (full text at CIViC)

PMID 24553387 · Misale et al., 2014 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

NRAS mutations have also been observed in melanoma and biliary tract, bladder, cervix, liver, lung, myeloid leukemia, ovarian, pancreatic, and thyroid cancer.

PMID 17384584 · Schubbert et al., 2007 · Open in CIViC

Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.

PMID 24666267 · Therkildsen et al., 2014 · Open in CIViC

A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xeno… (full text at CIViC)

PMID 22586653 · Bertotti et al., 2011 · Open in CIViC

The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC)

PMID 21641636 · Maughan et al., 2011 · Open in CIViC

In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC)

PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC

In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61, N=13) was not informative for disease control rate, progression free survival or overall survival follo… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Chemotherapy-refractory patients with KRAS wt metastatic colorectal cancer harboring NRAS mutation (primarily Q61, n=10) have a significantly lower response rate to cetuximab than patients wildtype fo… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In a retrospective study of 368 chemotherapy-refractory metastatic colorectal cancer, patients with a NRAS mutation (n=13) treated with cetuximab in combination with standard chemotherapy were associa… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS Q61H was wildtype for KRAS, BRAF and PIK3CA.… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In 11 melanoma patients harboring BRAF mutations, one patient with a Q61K NRAS mutation acquired resistance to the BRAF inhibitor vemurafenib. Q61K and/or A146T NRAS mutations have also shown resista… (full text at CIViC)

PMID 21107323 · Nazarian et al., 2010 · Open in CIViC

In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabiliza… (full text at CIViC)

PMID 22392911 · Migliardi et al., 2012 · Open in CIViC

Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61L and were wildtype for KRAS, BRAF and PI… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

NRAS mutations have also been observed in melanoma and biliary tract, bladder, cervix, liver, lung, myeloid leukemia, ovarian, pancreatic, and thyroid cancer.

PMID 17384584 · Schubbert et al., 2007 · Open in CIViC

Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61R and were wildtype for KRAS, BRAF and P… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabiliza… (full text at CIViC)

PMID 22392911 · Migliardi et al., 2012 · Open in CIViC